International Stem Cell Corp. (OTC: ISCO) shares spiked nearly 15% today, moving on recent word that the company launched the first phase of its joint marketing campaign with John Mauldin, founder and chairman of Millennium Wave Investments and is appointed to market Lifeline Skin Care’s new topical skin care products to more than 1 million of Mauldin’s subscribers.
The partnership will not only raise awareness of ISCO’s operations and developments, but is in line with ISCO’s earlier successful release to its own investor base and to the general public through its Web site.
Recently, the company also announced that it entered into an agreement with Aspire Capital Fund to provide up to $25 million of equity capital over the next three years. In relation to this transaction, Aspire purchased, upon execution of the agreement, 333,333 shares of ISCO Common Stock at a price of $1.50 per share, a 7% premium over Friday’s closing price of $1.40 per share. The pricing of future sales in the agreement will be determined each time as the company elects to sell shares to Aspire by a formula that is based on the actual sale prices of the company’s stock over the 12 days preceding each sale to Aspire.
International Stem Cell focuses on therapeutic biomedical research and cosmeceutical products.
- · Need fast service and cheap rates from a broker? Click here to see my favorite place to trade ISCO
- · Want more? Check out the message board buzz for ISCO
- · See which newsletters are recommending this stock pick
- · Get breaking news alerts on this stock: http://thestockmarketwatch.com/
BeaconEquity.com is committed to producing the highest-quality insight and analysis of small-cap stocks, emerging technology stocks, hot penny stocks and helping investors make informed decisions. Our focus is primarily OTC stocks in the stock market today, which have traditionally been shunned by Wall Street. We have particular expertise with renewable energy stocks, biotech stocks, oil stocks, green energy stocks and internet stocks. There are many hot penny stock opportunities present in the OTC market everyday and we seek to exploit these hot stock gains for our members before the average daytrader is aware of them.
Beacon Equity Group Disclaimer
This newsletter is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Beaconequity.com is a wholly-owned subsidiary of BlueWave Advisors.
While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.